ChemoCentryx, Inc. (CCXI)
CCXIPrice: $51.99
Fair Value: 🔒
🔒score
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of ad... more
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of... more
Description
Shares
| Market Cap | $0 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Thomas Schall |
| IPO Date | 2012-02-08 | CAGR | 0.02% |
| Employees | 178 | Website | www.chemocentryx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CCXI chart loading...
Fundamentals
Technicals
| Enterprise Value | $1.79B | P/E Ratio | -25.93 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 11.94 |
| P/CF Ratio | -45.16 | P/FCF Ratio | — |
| EPS | $-2 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 76.11% | Gross Margin | 0.99% |
| Operating Margin | -4.17% | Profit Margin | -4.01% |
| ROE | -0.38% | ROA | -0.3% |
| ROCE | -0.37% | Current Ratio | 4.27 |
| Quick Ratio | 4.26 | Cash Ratio | 0.79 |
| Debt/Equity | 0.02 | Interest Coverage | 49.89 |
| Altman Z Score | — | Piotroski Score | — |